Skip to main content
TipRanks
Go Ultimate75% OFF

Dr Reddy's Laboratories (RDY) AI Stock Analysis

457 Followers
RDY

Dr Reddy's Laboratories

(NYSE:RDY)

Select Model
Rating:67Neutral
Price Target:$16.00â–²(6.81% Upside)
Action:downgraded
Date:10/24/26

RDY scores in the upper-mid range primarily due to a strong balance sheet and still-healthy profitability, supported by constructive technical momentum (price above key moving averages with positive MACD). The score is held back by deteriorating cash-flow conversion and a near-term slowdown (TTM revenue decline and margin compression), along with a relatively expensive valuation (P/E ~31 and low dividend yield). Earnings-call commentary is a net positive on margin outlook and product catalysts, but tempered by cost pressures and regulatory/validation uncertainty.

Positive Factors
Conservative Balance SheetLow leverage gives Dr. Reddy’s financial flexibility to fund product development, manufacturing capacity, and strategic opportunities without relying heavily on borrowing. This conservative capitalization also provides resilience if pharmaceutical pricing, approvals, or operating cash generation remain volatile.
Negative Factors
Revenue and Margin SlowdownRecent revenue contraction and material margin compression weaken near-term earnings momentum and show that the established portfolio is not converting growth into prior profitability levels. Sustained pressure would reduce funds available for research, launches, and capacity expansion over coming quarters.

Dr Reddy's Laboratories (RDY) vs. SPDR S&P 500 ETF (SPY)

-20%-10%0%10%20%30%RDY+8.28%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$12.33B
Dividend Yield
0.76%
Average Volume (3M)
2.88M
Price to Earnings (P/E)
41.3
Beta (1Y)
0.29
Revenue Growth
-10.52%
EPS Growth
-55.45%
Country
US
Employees
27,527
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Dr Reddy's Laboratories Business Overview & Revenue Model

Company Description

Established in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited functions as a fully integrated global pharmaceutical entity. Its business is structured into several core divisions. The Global Generics segment is responsib...

How the Company Makes Money

Dr. Reddy’s makes money primarily by selling pharmaceutical products and related pharmaceutical inputs across multiple geographies. Key revenue streams include: (1) Generic formulations: The company develops or licenses generic versions of branded dr...

Dr Reddy's Laboratories Earnings Call Summary

Earnings Call Date:Oct 23, 2026(Q2-2027)|% Change Since:13.23%|Next Earnings Date:Jan 22, 2027
Earnings Call SentimentPositive

The call was predominantly positive. Management highlighted double-digit growth in the underlying business, strong emerging-market and India performance, sequential margin expansion, progress in semaglutide validation and launches, biosimilar and complex-generic opportunities, CDMO growth, and a strong net cash position. The main negatives were the 1.5% year-over-year consolidated revenue decline, lower Lenalidomide sales, declines in North America, Europe, and PSAI, higher input and logistics costs, and remaining regulatory and validation uncertainty around key products.

Positive Updates

Underlying Business Delivered Double-Digit Growth
Excluding Lenalidomide in North America, the underlying base business maintained its growth momentum and delivered double-digit growth overall and across North America, emerging markets, and India.

Negative Updates

Consolidated Revenue Declined Year Over Year
Consolidated revenue declined 1.5% year over year to ₹8.01 thousand crores, or US$905 million, despite increasing 7.4% sequentially.

Company Guidance

Management expects gross margin in the range 50% to 55% and R&D in the range of 7% to 8% in coming quarters; raw-material, solvent and freight pressures are expected to continue for Q3 and Q4. CapEx is expected to be around ₹1.6 thousand crore to ₹1.7 thousand crore versus earlier guidance of around ₹1.8 thousand crore. NRT is expected to grow somewhere between a high single digit to maybe even double digit, Europe is expected to deliver growth but it will not be significant growth this year, and ex-NRT Europe should grow probably single-digit this year. India is expected to stay a high level of double digit and remain higher than market growth. Semaglutide is expected to resume by November 2026 subject to successful validation, with 6 to 7 million devices this year and a 12 to 15 million pens run rate estimate; Brazil is likely in Q4, while smaller markets are expected to launch either in the end of Q3 or at the beginning of Q4. Abatacept has a December 22nd goal date, with ramp up after 6 months, a 15% to 25% fair market share initially for IV, and subcu expected in February 2028. CDMO is expected to reach 2x to 3x of these numbers in the next 3 to 4 years.

Dr Reddy's Laboratories Financial Statement Overview

Summary

Overall fundamentals are solid but recently pressured. Income statement remains healthy (gross margin ~50%, operating margin ~14%) yet shows a clear near-term slowdown with TTM revenue down and margin compression. Balance sheet is a strength with low leverage (~0.19x debt/equity), though ROE has cooled (~9% TTM). The key drag is cash flow quality: weaker operating cash flow vs earnings and low/declining free-cash-flow conversion.

Income Statement

72Positive

Balance Sheet

80Positive

Cash Flow

54Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue331.38B353.47B325.54B279.16B245.88B214.39B
Gross Profit163.93B186.52B190.43B163.61B139.34B113.84B
EBITDA53.96B83.29B96.67B88.42B74.43B45.08B
Net Income28.03B45.09B56.54B55.68B45.07B23.57B
Balance Sheet
Total Assets577.00B567.88B492.99B387.52B321.85B292.83B
Cash, Cash Equivalents and Short-Term Investments76.58B86.08B57.91B81.47B61.80B44.37B
Total Debt72.60B75.81B46.77B20.02B13.47B33.84B
Total Liabilities185.92B194.95B155.82B106.97B90.86B102.30B
Stockholders Equity387.87B369.60B333.39B280.55B230.99B190.53B
Cash Flow
Free Cash Flow12.01B32.10B12.03B18.00B40.01B9.06B
Operating Cash Flow30.11B56.65B46.43B45.43B58.88B28.11B
Investing Cash Flow-31.03B-70.53B-58.08B-40.28B-41.37B-26.39B
Financing Cash Flow3.08B13.40B18.91B-3.76B-26.86B-2.42B

Dr Reddy's Laboratories Technical Analysis

Technical Analysis SentimentPositive
Last Price14.98

Price Trends

50DMA13.15Positive
100DMA12.84Positive
200DMA13.25Positive

Market Momentum

MACD0.50Positive
RSI69.58Neutral
STOCH56.07Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDY, the sentiment is Positive. The current price of 14.98 is above the 20-day moving average (MA) of 14.30, above the 50-day MA of 13.15, and above the 200-day MA of 13.25, indicating a bullish trend. The MACD of 0.50 indicates Positive momentum. The RSI at 69.58 is Neutral, neither overbought nor oversold. The STOCH value of 56.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RDY.

Dr Reddy's Laboratories Risk Analysis

Dr Reddy's Laboratories disclosed 60 risk factors in its most recent earnings report. Dr Reddy's Laboratories reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Dr Reddy's Laboratories Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

RDY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ANIPANIP72Outperform$1.59B13.5220.00%―25.94%203.25%
VTRSVTRS67Neutral$23.44B-38.69-4.24%2.35%4.80%82.97%
RDYRDY67Neutral$12.37B41.317.37%0.76%-10.52%-55.45%
TEVATEVA65Neutral$49.04B100.359.18%―2.99%-28.63%
AMRXAMRX58Neutral$7.36B48.70131.71%―8.88%2272.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ALVOALVO43Neutral$1.56B-5.4697.21%―-14.25%-417.72%

* Healthcare Sector Average

Performance Comparison

0%50%100%RDYVTRSTEVAANIPAMRXALVODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
RDY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RDYDr. Reddy's Laboratories Ltd14.981.168.36%
VTRSViatris, Inc.20.2810.44106.08%
TEVATeva Pharmaceutical Industries Limited42.2316.2362.42%
ANIPAni Pharmaceuticals71.47-7.05-8.98%
AMRXAmneal Pharma21.8810.3690.01%
ALVOAlvotech4.55-0.51-10.08%

Dr Reddy's Laboratories Corporate Events

Dr. Reddy’s Reports VAI Classification and Closure of FTO-3 USFDA Inspection

Nov 16, 2026

Dr. Reddy’s Laboratories Ltd. is the reporting company in the filing, which concerned its formulations manufacturing facility, FTO-3, in Bachupally, Hyderabad.On November 14, 2026, the company reported that the USFDA had classified the outcome of its...

Dr. Reddy’s Wins Brazilian Authorization for Generic Semaglutide

Nov 5, 2026

Dr. Reddy’s Laboratories is a Hyderabad-based global pharmaceutical company producing APIs, generics, branded generics, biosimilars and over-the-counter medicines, with therapeutic focus including diabetology and major markets including India, the Un...

Dr. Reddy’s Allots 591,270 Shares Under Employee Stock Options

Nov 4, 2026

Dr. Reddy’s Laboratories is an India-based pharmaceutical company that develops and markets generic medicines, biosimilars and proprietary products across global markets. Its shares are listed in India and the United States through equity and America...

Dr. Reddy’s Files SEC Form 6-K and Publishes Q2 FY27 Earnings Call Transcript

Oct 29, 2026

Dr. Reddy’s Laboratories, a Hyderabad-based global generic pharmaceutical manufacturer listed in India and the U.S., continues to operate as a widely held, internationally regulated issuer in the healthcare sector. Its securities trade under the tick...

Dr. Reddy’s Gets Favorable USFDA VAI Status at Srikakulam Plant

Oct 29, 2026

Dr. Reddy’s Laboratories has reported the outcome of a U.S. Food & Drug Administration inspection at its FTO-SEZ Process Unit-02 facility in Srikakulam, Andhra Pradesh. The inspection, originally conducted as a Pre-Approval Inspection and Good Manufa...

Dr. Reddy’s Files Unmodified Auditor Review on September 2026 Interim Results

Oct 26, 2026

Dr. Reddy’s Laboratories has submitted a Form 6-K to the U.S. Securities and Exchange Commission dated October 24, 2026, furnishing an intimation from October 23, 2026 regarding its unaudited consolidated financial results for the quarter and half ye...

Dr. Reddy’s Files Form 6-K, Publishes Q2 FY27 Earnings Call Recordings

Oct 26, 2026

Dr. Reddy’s Laboratories has filed a Form 6-K with the U.S. Securities and Exchange Commission in October 2026, formally furnishing an intimation dated October 24, 2026, signed by Company Secretary K. Randhir Singh. The filing underscores the company...

Dr. Reddy’s Laboratories Files Q2 FY 2027 Unaudited Results with SEC and Indian Exchanges

Oct 23, 2026

On October 23, 2026, Dr. Reddy’s Laboratories announced its unaudited financial results for the quarter and half-year ended September 30, 2026, covering both consolidated and standalone performance. The disclosures were prepared under International F...

Dr. Reddy’s Elevates Aurigene CEO Akhil Ravi to Head API and Services

Oct 23, 2026

Dr. Reddy’s Laboratories has strengthened its senior leadership structure with a new appointment in its active pharmaceutical ingredients (API) and services division, underlining the strategic importance of CRDMO and CDMO operations to the group’s gr...

Dr. Reddy’s Releases Q2 FY27 Unaudited Results Presentation

Oct 23, 2026

Dr. Reddy’s Laboratories Limited is a global pharmaceutical company based in Hyderabad, India, focused on developing, manufacturing and marketing generic and branded formulations, active pharmaceutical ingredients and biosimilars. The company’s share...

Dr. Reddy’s Interim Q2 FY 2026 Results Receive Clean Auditor Review

Oct 23, 2026

Dr. Reddy’s Laboratories Limited has filed a Form 6-K containing its unaudited condensed consolidated interim financial statements for the quarter and six‑month period ended September 30, 2026. The statements are prepared in accordance with IAS 34 an...

Dr. Reddy’s Receives USFDA Form 483 After Pre-Approval Inspection at Visakhapatnam Plant

Oct 14, 2026

The U.S. Food and Drug Administration completed a pre-approval inspection at Dr. Reddy’s FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh, held from October 8 to October 9, 2026. The plant, which supports the company’s regulated-market a...

Dr. Reddy’s Receives Two-Observation USFDA Form 483 After PAI at FTO-11

Oct 8, 2026

Dr. Reddy’s Laboratories has disclosed that the U.S. Food and Drug Administration recently conducted a Pre-Approval Inspection at its FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh. The inspection took place from October 5 to October...

Dr. Reddy’s Sets October 23 Date for Q2 FY27 Results and Global Earnings Call

Oct 7, 2026

Dr. Reddy’s Laboratories announced on October 7, 2026 that it will release its financial results for the quarter and six months ended September 30, 2026 on Friday, October 23, 2026, following a meeting of its board of directors. The company has sched...

Dr. Reddy’s U.S. Subsidiary Hit with Modest IRS Penalty, Assessed as Non‑Material

Oct 5, 2026

On October 3, 2026, Dr. Reddy’s Laboratories Limited disclosed that its U.S. step‑down wholly owned subsidiary, Dr. Reddy’s Laboratories, Inc., received a final transcript from the Internal Revenue Service dated September 25, 2026, which was delivere...

Dr. Reddy’s Schedules October 23 Board Meet, Closes Trading Window Ahead of Q2 Results

Sep 22, 2026

Dr. Reddy’s Laboratories has notified stock exchanges that its Board of Directors will meet on October 23, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter ended September 30, 2026. The disclosure,...

Dr. Reddy’s Schedules Nomura-Led Investor Meet in Hyderabad

Sep 21, 2026

Dr. Reddy’s Laboratories filed a Form 6-K with the U.S. Securities and Exchange Commission dated September 21, 2026, as part of its ongoing obligations as a foreign private issuer listed on the New York Stock Exchange. The filing, signed by Company S...

Dr. Reddy’s, Takeda Seal Exclusive Deal to Launch First Approved Dengue Vaccine in India’s Private Market

Sep 18, 2026

On September 18, 2026, Dr. Reddy’s Laboratories signed an exclusive agreement with Takeda Biopharmaceuticals India to distribute and market Takeda’s dengue vaccine Qdenga in India’s private market. Under the deal, Dr. Reddy’s will handle promotion an...

Dr. Reddy’s Reports FDA Records Assessment at Mexican API Plant Concluding with Two Observations

Sep 14, 2026

Dr. Reddy’s Laboratories disclosed that the U.S. Food and Drug Administration completed a records assessment at its API manufacturing facility, Industrias Químicas Falcón de México (Dr. Reddy’s Mexico), in Jiutepec, Morelos, Mexico. The review, condu...

Dr. Reddy’s Issues New ESOP Shares After ADR Option Exercise

Sep 10, 2026

On September 10, 2026, Dr. Reddy’s Laboratories allotted 375 fully paid equity shares of Re.1 each to eligible employees following the exercise of stock options under its Employees ADR Stock Option Scheme, 2007. The new issuance marginally increases...

Dr. Reddy’s Schedules September Analyst and Investor Meetings

Sep 10, 2026

On September 10, 2026, Dr. Reddy’s Laboratories filed a regulatory update noting its participation in upcoming analyst and institutional investor conferences. The company’s management plans an in-person group meeting with ICICI Securities in Hyderaba...

Dr. Reddy’s Laboratories Allots New Shares Under Employee Stock Option Scheme

Aug 26, 2026

On August 26, 2026, Dr. Reddy’s Laboratories informed the BSE, NSE, NYSE and NSE IFSC that it had allotted 4,110 fully paid equity shares of face value Re.1 each to eligible employees exercising options under the Dr. Reddy’s Employees Stock Option Sc...

Dr. Reddy’s Receives USFDA Form 483 for Bachupally Plant After August Inspection

Aug 17, 2026

Dr. Reddy’s Laboratories has disclosed that the U.S. Food & Drug Administration completed a good manufacturing practice inspection of its formulations plant FTO-3 in Bachupally, Hyderabad, conducted between August 6 and August 14, 2026. The inspectio...

Dr. Reddy’s Receives VAI Classification as USFDA Closes Inspection of U.K. API Plant

Aug 17, 2026

On August 14, 2026, Dr. Reddy’s Laboratories reported that a U.S. Food & Drug Administration good manufacturing practice inspection of its API facility in Mirfield, West Yorkshire, U.K., conducted earlier and first disclosed on September 8, 2025, has...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 24, 2026